▷ Moderna Dividends 【Calendar 2025】

Upcoming Moderna dividend

Change(%)

0.00%

No change

Next payment N/A

Next payment date N/A

Last payment N/A

Last payment date N/A

00 D 00 H 00 M 00 S

Ex-Dividend: N/A

Not available

When are the upcoming Moderna dividends in 2025?

▶

There are no dividend projections for this year from Moderna.

Dividend policy of Moderna

▶

Moderna, listed on the American stock exchange under the ticker symbol MRNA, although to date it has not paid dividends to its shareholders and has not yet announced any change in this policy.

Payout Ratio Moderna Dividends

In the last fiscal period, Moderna paid no dividends, resulting in a dividend payout ratio of 0%.

Moderna has not distributed dividends in the last fiscal period, therefore, the payout ratio is 0%.

Dividend payout ratio Payout Ratio

Dividend calendar of Moderna

There is no Dividend Calendar of Moderna defined for 2025.

Information about Moderna

Full name Moderna, Inc.

Ticker MRNA

Sector Health Care

Industry Biotechnology

Market Capitalization 13.07B $

ISIN US60770K1079

Number of Employees 3,900

Description of the company

Moderna, is a company dedicated to biotechnology and creation of drugs or vaccines based on the use of messenger RNA.

Its name is derived from the union between the words "modified" and "RNA", was founded in 2010 and begins its activities in 2011, conducted trials with other laboratories such as AstraZeneca, Mark and Alexion Pharmaceuticals, but in 2014 they decide to focus exclusively on their methodology and create vaccines based on mRNA.

In 2017 they create and commercialize the human vaccine mRNA-1653, with multivalent effect, protecting against human metapneumovirus (hMPV) and parainfluenza virus.

In 2020, because of the COVID-19 pandemic, they gained media attention by announcing that their experimental vaccine against the virus had successfully passed the first and second phase of the study by producing antibodies, although by then the possibility of generating side effects had not been controlled.

However, they were able to determine that if applied in low doses the adverse reactions (which could range from headache, fatigue, muscle pain to fever) decreased considerably, so it was studied with two doses of 100 mg administered at an interval of 29 days, obtaining approval in December of that year, being the second to be accepted worldwide.

Its headquarters are located in Massachusetts, United States, its business is mainly based on the insertion of the synthetic mRNA chain to live cells to try to reprogram them and develop an immune behavior, methodology used in previous opportunities by other laboratories, but abandoned for not being able to minimize the side effects that were generated, which is why, except for vaccines, the drugs produced by Moderna have not yet been approved to be marketed.